Hims & Hers Teams Up with Novo Nordisk to Expand FDA-Approved GLP-1 Options in US Weight Loss

Hims & Hers Health announced a strategic shift in its US weight‑loss business, partnering with Novo Nordisk to broaden access to FDA‑approved GLP‑1 therapies on its platform, while phasing out most compounded GLP‑1 offerings (with access preserved only where clinically necessary). The plan includes adding Novo Nordisk products like Ozempic and Wegovy, aligning US and global models, and educating customers to transition to FDA‑approved treatments, aiming to create a large global consumer health platform for affordable medications. The move follows a rapidly evolving GLP‑1 landscape, and Novo Nordisk’s lawsuit against Hims & Hers was dismissed without prejudice.